Phase 2 Study Evaluating the Safety and Efficacy of Eloxatin (Oxaliplatin) and Docetaxel as First-Line Therapy of Stage IV or IIIB Unresectable Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2016
At a glance
- Drugs Docetaxel (Primary) ; Oxaliplatin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Jul 2007 The expected completion date for this trial is now 1 Dec 2007.
- 05 Nov 2006 New trial record.